Why BGPT?
logo

Review papers with raw data transparency

Quickly verify claims by accessing the underlying experimental data and figures.







Press Enter ↡ to solve



    Fuel Your Discoveries




     Quick Explanation


    Paper Review Summary

    The reviewed article is a 2025 narrative review synthesizing evidence that CD99 (MIC2) is a multifunctional transmembrane regulator at the immune cell tumor interface, with isoform dependent effects on adhesion, trafficking, cell death, myeloid polarization, and tumor biology; it proposes anti-CD99 strategies as immunomodulatory and direct antitumor interventions but notes important translational caveats including isoform specificity and limited clinical data




     Long Explanation


    Detailed Critical Review and Analysis

    1. What the paper claims (verbatim synthesis)

    The authors present CD99 as a context dependent regulator linking immune response and tumor microenvironment functions: CD99wt (type I, 185 aa, 32 kDa) and CD99sh (type II, 161 aa, 28 kDa) have different phosphorylation sites and distinct cellular roles; CD99 engages in homotypic and selected heterotypic interactions (eg PILRalpha/b and GDF6 in Ewing sarcoma), modulates T cell co-stimulation, MHC trafficking, diapedesis, dendritic cell maturation (CD1a regulation), macrophage polarization (M0/M2 to M1 on CD99 triggering), leukemic stemness, tumor invasion/metastasis, and is a candidate therapeutic target with monoclonal antibodies, small molecules, and CAR approaches. The review explicitly emphasizes isoform specificity, the dual immunoregulatory/oncogenic roles of CD99, and translational opportunities and caveats

    2. Strengths

    • Comprehensive literature synthesis spanning molecular structure, isoforms, immune cell biology, tumor models, and therapeutic attempts; useful for researchers entering the field

      8. Final balanced verdict

      The review is a useful, well-referenced synthesis that meaningfully advances a field-level view of CD99 as a multifunctional regulator linking immune function and tumor biology. It correctly emphasizes isoform biology and translational promise. However, because much evidence remains preclinical and isoform-resolving reagents are lacking, clinical application of anti-CD99 therapies requires careful, context-specific preclinical testing focused on isoform effects and safety. Overall the review is valuable for researchers and translational teams as a roadmap but should not be used as direct justification for clinical trials without the additional experiments outlined above

      Interactive next steps





      Citation for all claims in this review and source for extracted data:



    Feedback:    

    Updated: September 21, 2025

     BGPT Paper Review


    Study Novelty

    70%

    The review consolidates recent and diverse findings (ligands, isoforms, macrophage reprogramming, EV biomarkers) and situates them in translational context; novelty is moderate-high because it integrates new single-cell and ligand-discovery data but does not present primary data.


    Scientific Quality

    80%

    High-quality narrative synthesis (141 refs) with mechanistic detail and translational framing; limitations are those of narrative reviews (selection bias, lack of systematic risk-of-bias assessment, and reliance on preclinical studies).


    Study Generality

    70%

    Generality is moderate: CD99 biology spans many immune and tumor contexts (broad relevance) but functional outcomes are context- and isoform-dependent, limiting uniform generalization.


    Study Usefulness

    80%

    Useful as a roadmap for research and translational teams (identifies isoform issues, candidate ligands, macrophage reprogramming); directly suggests testable therapeutic strategies though clinical translation is not yet mature.


    Study Reproducibility

    60%

    As a review reproducibility depends on the primary literature; methods for literature selection are not systematic and many primary studies use heterogeneous models making reproducibility of inferred conclusions moderate.


    Explanatory Depth

    80%

    Provides mechanistic hypotheses (TGN to membrane trafficking, MAPK activation, ligand interactions such as GDF6–CSK recruitment) and connects molecular to cellular to TME level; depth limited by available primary mechanistic data.


    🎁 Authors: Collect 301 Free Science Tokens (β‰ˆ $30.1 USD)

    Claim My Author Tokens

    Use for 75 days of free BGPT access (4 tokens = 1 day) or trade/sell (β‰ˆ $30.1 USD)

     Top Data Sources ExportMCP


     Analysis Wizard



    Preparing isoform expression matrices from scRNA-seq and bulk GTEx/TCGA data to compute CD99wt/CD99sh ratios and correlate with macrophage markers and immune signatures (uses TCGA, GTEx, and provided review-extracted gene lists).



     Hypothesis Graveyard


    CD99 expression alone is a reliable pan-cancer therapeutic biomarker β€” falsified because isoform balance and tumor context change functional outcome.


    Anti-CD99 systemic therapy will be universally safe since expression is tumor-restricted β€” falsified by CD99 high expression in thymus and endothelium suggesting on-target toxicities.

     Science Art


    Paper Review: CD99: A Key Regulator in Immune Response and Tumor Microenvironment Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion








    Get Ahead With Science Insights

    Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.


    My BGPT






     Trending